Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials

Immunotherapy 2026 Open access

Read full text
Authors: Akhil Deepak Vatvani, Gilbert Lazarus, Reyad Al Jabiri, Rama Nada, Maria Albuja Altamirano, Eunhee Choi, Nehad Shabarek
DOI: 10.1080/1750743x.2026.2665031
Cited by: 1
References: 24

Abstract

INTRODUCTION: Pembrolizumab plus chemotherapy is widely used as first-line treatment for advanced NSCLC, but its benefit in patients with low PD-L1 expression remains uncertain. This study evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in advanced or metastatic NSCLC with PD-L1

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations

Publication details

Journal / source
Immunotherapy
Publisher
Informa UK Limited
Volume
18
Issue
4
Pages
339–349
Publication date
4 March 2026
Language
EN